Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Objective
Methods
Results
Conclusion
Keywords
Enterohemorrhagic Escherichia coli is a subset of Shiga toxin-producing E. coli that can cause
diarrhea or hemorrhagic colitis in humans. Hemorrhagic colitis occasionally progresses to hemolytic
uremic syndrome, is a major cause ofacute renal failure in children and morbidity and mortality in
adults.
To determine the susceptibility and resistance of the most effective antibiotic to E.coli O157:H7
associated with bloody diarrhea.
Two hundred patients with bloody diarrhea were enrolled in this study. Escherichia coli were
isolated on Sorbitol MacConkey agar with Cefixime and Tellurite and tested by latex agglutination
test. The susceptibility and resistance for all bacterial isolates were identified by standard
procedures resistance patterns such as disk diffusion test and minimum inhibitory concentration.
E.coli O157:H7 found in 37 (18.5%) out of two hundred stool samples. The highest rate was found in
18 cases (48.64%) out of 37 infants aged 3-12 months, 12 cases (32.43%) in infants aged 13-24
months, and the lower rates was in children over two years old (18.9%). E.coli O157: H7 was
completely resistant to gentamicin, ampicillin, nalidixic acid and co-trimoxazole; high rate of
resistance to cefotaxime and ceftazidime, moderate-to-low rate of resistance to ciprofloxacin,
amikacine, ceftriaxone and Imipenem and no resistances rate to levofloxacin. Out of 37 isolates 29
(78.3%) were -lactamase producer and 8 (21.6 %) isolates resistant to -lactamase antibiotic
patterns but not produce -lactamase enzyme.
The high-incidence rate of E. coli O157:H7 infection in children associated with limited number of
drugs effective against E. coli O157:H7 with high prevalence of resistance to more than three
antibiotics.
E.coli O157:H7, Enterohemorrhagic Escherichia coli, disk diffusion test, minimum inhibitory
concentration.
Introductions
nterohemorrhagic
Escherichia
coli
(EHEC) is a subset of Shiga toxin (Stx)producing E. coli that can cause diarrhea
or hemorrhagic colitis in humans. Hemorrhagic
colitis occasionally progresses to hemolytic
Escherichia coli
Positive
Negative
No. (%)
No. (%)
18 (25.7)
52 (74.3)
7 (16.7)
35 (83.3)
12 (13.6)
76 (86.4)
37 (18.5)
163 (81.5)
Total
70
42
88
200
RI
37
37
37
20
25
15
18
17
0
5
37
SI
0
0
0
17
12
22
19
20
37
32
0
R%
100
100
100
54
67.5
40.5
48.6
45.9
0
13.5
100
References
1. Bielaszewska M, Kck R, Friedrich AW, et al. Shiga
toxin-mediated hemolytic uremic syndrome: time to
change the diagnostic paradigm? PLoS ONE. 2007;
2:e1024.
2. Alam MJ, Zurek L. Seasonal prevalence of Escherichia
coli O157:H7 in beef cattle feces. J Food Prot. 2006;
69:3018-20.
3. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli.
Clin Microbiol Rev. 1998; 1:142-201.
4. World Healths Organization (WHO). The world health
report
1996Fighting
disease,
fostering
Development. World Health Forum 1997; 18:1-8.
5. Karlowsky JA, Jones ME, Thornsberry C, et al. Trends
in
antimicrobial
susceptibilities
among
Enterobacteriacae isolated from hospitalized patients
in the United States from 19982001. Antimicrob
Agents Chemother. 2003; 47:1672-1680.
6. Blake DP, Humphry RW, Scott KP, et al. Influence of
tetracycline exposure on tetracycline resistance and
the carriage of tetracycline resistance genes within
commensal Escherichia coli populations. J Appl
Microbiol. 2003; 94:1087-1097.
7. Carattoli A. Resistance plasmid families in
Enterobacteriaceae. Antimicrob Agents Chemother.
2009; 53:2227-2238.
8. Wong CS, Jelacic S, Habeeb RL, et al. The risk of
hemolytic-uremic
syndrome
after
antibiotic
treatment of Escherichia coli O157:H7 infections. N
Engl J Med. 2000; 342:1930-1936.
9. Zhang XN, McDaniel AD, Wolf LE, et al. Quinolone
antibiotics
induce
Shiga
toxin-encoding
bacteriophages, toxin production, and death in mice.
J Infect Dis. 2000; 181:664-670.
10. Shiomi M, Togawa M, Fujita K, et al. Effect of early
oral fluoroquinolones in hemorrhagic colitis due to
Escherichia coli O157:H7. Pediatr Int. 1999; 41:228232.
11. Brooks GF, Carroll KC, Butel JS, et al. Jawetz, Melnick,
th
& Adelbergs Medical Microbiology. 26 ed. USA: The
McGraw-Hill Companies; 2013. Pp. 234.
12. David ML, Derek FJ. Detection of -lactamasemediated resistance J Antimicrob Chemother. 2001;
48 (suppl. 1):59-64.
13. Clinical laboratory standard institute: Performance
th
standards for antimicrobial susceptibility testing, 19
informational supplement. CLSI document 2009;
M100S19. WAYNE (PA).
14. Wiegand I, Hilpert K Hancock R. Agar and broth
dilution methods to determine the minimal inhibitory
concentration (MIC) of antimicrobial substances.
2008 JAN; 3(2), 163-175. Available from:
WWW//:PTTH.NATURE.COM/NATURE PROTOCOLS.
15. Baqir HE, Al-Hashemi AB, Althwani NA.
Microbiological study of Escherichia coli O157:H7
isolated from bloody diarrhea in children under ten
years old. Iraqi J Sci. 2008; 49:90-94.
263
264
th
Diseases and 25
International Congress of
Chemotherapy; March 31-April 3 2008. p. 45-50.
23. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak
of ceftazidime resistance caused by extendedspectrum beta-lactamases at a Massachusetts
chronic-care facility. J Antimicrob Agents Chemother.
1990; 34:2193-219.
24. Tadesse TA, Zhao S, Tong E, et al. Antimicrobial Drug
Resistance in Escherichia coli from Humans and Food
Animals, United States, 1950-2002. Emerg Infec Dis.
2012; 18:741-749.
25. Schroeder CM, Zhao C, DebRoy C, et al. Antimicrobial
resistance of Escherichia coli O157:H7 isolated from
humans, cattle, swine, and food. J Appl Environ
Microbiol. 2002; 68:76-581.
26. Reuben RC, Owuna G. Antimicrobial resistance
patterns of Escherichia Coli O157:H7 from Nigerian
fermented milk samples in Nasarawa State, Nigeria.
Int J Pharmac Sci Inv. 2013; 2:38-44.
27. Stephan R, Ragettiy S, Unterma F. Prevalence and
characteristics of verotoxin-producing Escherichia
coli (VTEC) in stool samples from asymptomatic
human carriers working in the meat processing
industry in Switzerland. J Appl Microbiol. 2000;
88:335-341.
E-mail: jabbarsalman30@yahoo.com
Tel. + 964 7802559522
th
th
Received 24 Jun.2015: Accepted 30 Sep. 2015